Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Clesrovimab is a new monoclonal antibody for preventing RSV lower respiratory tract infections in infants. It shows high efficacy, favorable safety, and practical advantages over other options.
Area Of Science
- Immunology
- Pediatrics
- Virology
Background
- Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants.
- Existing prevention strategies include palivizumab and nirsevimab, with varying efficacy and administration requirements.
- The FDA recently approved clesrovimab-cfor (Enflonsia®) for RSV prevention in infants.
Purpose Of The Study
- To evaluate the clinical utility of clesrovimab for preventing RSV lower respiratory tract infections in infants.
- To compare the efficacy, safety, and pharmacokinetic profile of clesrovimab with existing monoclonal antibodies.
- To assess the practical advantages of clesrovimab, including dosing and stability.
Main Methods
- Literature search for clesrovimab, RSV, pediatric, and infant studies.
- Review of data from CDC, ACIP, FDA prescribing information, and manufacturer data.
- Inclusion of English-language studies on pharmacokinetics, pharmacodynamics, efficacy, and safety, including CLEVER and SMART trials and cost-effectiveness models.
Main Results
- Clesrovimab targets a conserved site on the RSV F protein, effective against pre- and postfusion forms.
- The CLEVER trial demonstrated a 60.4% reduction in RSV-associated medical visits and an 84.2% reduction in hospitalizations.
- The SMART trial indicated comparable efficacy and safety to palivizumab, with mild, injection-site related adverse events. Pharmacokinetics support single-dose administration with a 44-day half-life.
Conclusions
- Clesrovimab offers simplified dosing, favorable safety, and potential cost savings compared to palivizumab and nirsevimab.
- Its unique binding site and room-temperature stability provide practical advantages, despite nirsevimab's longer half-life.
- Further research is needed to confirm its role in high-risk populations and second seasons, but clesrovimab is a promising addition to infant RSV prevention.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
• Ventilation-Perfusion (V/Q)...
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...